Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus FEMTRACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus FEMTRACE.
DIETHYLSTILBESTROL vs FEMTRACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estrogen receptor agonist; binds to estrogen receptors, modulating gene transcription and cellular proliferation in target tissues.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
1 to 2 mg orally once daily; for testosterone replacement in adult males, 2 to 4 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 12-14 hours, supporting once-daily dosing in clinical use.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Primarily renal; ~40% as unchanged drug and glucuronide conjugates. Biliary/fecal elimination is minor (~10-15%).
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."